tetano
Editor, Senior Moderator
Pharmacol Res. 2020 Apr 15:104832. doi: 10.1016/j.phrs.2020.104832. [Epub ahead of print]
Angiotensin Receptor Blockers and 2019-nCoV.
Saavedra JM[SUP]1[/SUP].
Author information
Abstract
Angiotensin Receptor Blockers (ARBs) exhibit major pleiotropic protecting effects beyond their antihypertensive properties, including reduction of inflammation. ARBs directly protect the lung from the severe acute respiratory syndrome as a result of viral infections, including those from coronavirus. The protective effect of ACE2 is enhanced by ARB administration. For these reasons ARB therapy must be continued for patients affected by hypertension, diabetes and renal disease, comorbidities of the current 2019-nCoV pandemic. Controlled clinical studies should be conducted to determine whether ARBs may be included as additional therapy for 2019-nCoV patients.
Copyright ? 2020 Elsevier Ltd. All rights reserved.
KEYWORDS:
ACE2; Angiotensin Receptor Blockers; COVID-19; SARS-CoV-2; coronavirus
PMID:32304747DOI:10.1016/j.phrs.2020.104832
Angiotensin Receptor Blockers and 2019-nCoV.
Saavedra JM[SUP]1[/SUP].
Author information
Abstract
Angiotensin Receptor Blockers (ARBs) exhibit major pleiotropic protecting effects beyond their antihypertensive properties, including reduction of inflammation. ARBs directly protect the lung from the severe acute respiratory syndrome as a result of viral infections, including those from coronavirus. The protective effect of ACE2 is enhanced by ARB administration. For these reasons ARB therapy must be continued for patients affected by hypertension, diabetes and renal disease, comorbidities of the current 2019-nCoV pandemic. Controlled clinical studies should be conducted to determine whether ARBs may be included as additional therapy for 2019-nCoV patients.
Copyright ? 2020 Elsevier Ltd. All rights reserved.
KEYWORDS:
ACE2; Angiotensin Receptor Blockers; COVID-19; SARS-CoV-2; coronavirus
PMID:32304747DOI:10.1016/j.phrs.2020.104832